Peritoneal Mesothelioma

Peritoneal mesothelioma forms in the lining of the abdomen, called the peritoneum. It makes up around 10% of mesothelioma diagnoses and has the best prognosis of all types. Symptoms include abdominal pain, bloating, and fluid buildup in the abdomen. Surgery with heated chemotherapy has helped some peritoneal mesothelioma patients survive for 5+ years.

What Is Peritoneal Mesothelioma?

Peritoneal mesothelioma is an asbestos-caused cancer that develops in the peritoneum. The peritoneum is a thin membrane that covers the abdominal cavity and the organs inside it, such as the stomach, liver, spleen, and intestines.

Peritoneal Mesothelioma affects lining of the lungs
Peritoneal Mesothelioma
*affects lining of the abdominal cavity

More rare than its counterpart that develops in the lungs, peritoneal mesothelioma affects about 600 Americans each year.

Despite being the second most common type of mesothelioma, peritoneal mesothelioma has the most favorable prognosis. Patients who undergo cytoreductive surgery with HIPEC live for 5 years or more, in many cases.

How Peritoneal Mesothelioma Develops

  1. Exposure: Asbestos fibers are swallowed or inhaled and become trapped in the stomach lining.
  2. Buildup: Over time, the fibers irritate healthy cells and damage cell DNA, causing cancer cells to grow and the peritoneum to thicken.
  3. Damage: Mesothelioma cells continue growing and spreading, eventually forming tumors.
  4. Cancer: The invasive peritoneal tumors progress rapidly until treatments help to slow their growth.

Who Is at Risk for Peritoneal Mesothelioma?

People at high risk of asbestos exposure are generally more likely to develop peritoneal mesothelioma. High-risk groups include blue-collar workers, veterans, and those who live near asbestos mines or natural deposits.

Loved ones of individuals exposed to asbestos may also be at higher risk through secondhand exposure.

“I got peritoneal mesothelioma from working with my dad. He was a subcontractor, and he used to take us with him on his job sites.”

– Brenda W., Peritoneal Mesothelioma Victim

Peritoneal Mesothelioma Symptoms

Common symptoms of peritoneal mesothelioma include:

  • Abdominal fluid buildup (ascites)
  • Abdominal pain
  • Bloating (abdominal distention)
  • Fever and night sweats
  • Fatigue
  • Nausea and vomiting
  • Loss of appetite
  • Unexplained weight loss

The symptoms of malignant peritoneal mesothelioma may not appear until 20-50 years after the initial exposure to asbestos. These symptoms tend to be mild and vague, so many patients aren’t diagnosed until after their cancer has spread.

Mesothelioma Guide 2021 on iPad
Free Downloadable GuideMesothelioma Guide 2021
  • Latest Treatment Information
  • Financial Assistance for Treatment
  • VA Benefits Help

Get Your Free Guide

Peritoneal Mesothelioma Diagnosis

In order to confirm a peritoneal mesothelioma cancer diagnosis, your doctor must perform a biopsy. They may also use imaging tests to look for signs of cancer and rule out other diseases.

Imaging Tests

Imaging tests are the first step in the diagnostic process for peritoneal mesothelioma. Patients who report abdominal pain and swelling may receive X-rays, a computed tomography scan (CT scan), or magnetic resonance imaging (MRI).

Biopsies

Next, if your doctor suspects cancer, they will perform a biopsy. During this procedure, your doctor will collect a fluid or tissue sample and examine it under a microscope to see if cancer cells are present.

Types of biopsies for peritoneal mesothelioma include fine-needle aspiration, core needle biopsy, or diagnostic laparoscopy. Although biopsies are more invasive than imaging tests, doctors rely on them to make a confident diagnosis.

Diagnosing Peritoneal Mesothelioma Stage

Peritoneal mesothelioma is not staged using the typical Tumor Node Metastasis (TNM) cancer staging system because it advances in an unusual way, often remaining in the abdomen instead of spreading to other parts of the body.

Peritoneal mesothelioma is instead classified as early or advanced.

Getting a Second Opinion

Because peritoneal mesothelioma is a rare cancer, even an experienced oncologist can misdiagnose it — which could delay or eliminate the possibility of curative treatment.

If you have any questions about your diagnosis, it’s critical to get a second opinion from a specialized mesothelioma doctor.

We can help you find a specialist near you — contact us today.

Mesothelioma Support Team
Reviewed by:Dr. Mark Levin

Certified Oncologist and Hematologist

  • Fact-Checked
  • Editor

Mark Levin, MD has nearly 30 years of experience in academic and community hematology and oncology. In addition to serving as Chief or Director at four different teaching institutions throughout his life, he is also still a practicing clinician, has taught and designed formal education programs, and has authored numerous publications in various fields related to hematology and oncology.

Dr. Mark Levin is an independently paid medical reviewer.

Mesothelioma Hope was founded by a team of advocates to educate people about this aggressive form of cancer. Mesothelioma affects thousands of people each year. We help give hope to those impacted by mesothelioma.

View 14 References
  1. Kim, J., Bhagwandin, S., & Labow, D. M. (2017). Malignant peritoneal mesothelioma: a review. Annals of translational medicine, 5(11), 236. Retrieved August 26, 2020, from doi:10.21037/atm.2017.03.96
  2. The American Cancer Society medical and editorial content team. (2017). Core Needle Biopsy of the Breast. Retrieved January 16, 2020, from https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy/core-needle-biopsy-of-the-breast.html
  3. U.S. National Library of Medicine. (2018). Diagnostic laparoscopy. Retrieved January 16, 2020, from https://medlineplus.gov/ency/article/003918.htm
  4. Sugarbaker, P. H. (2019). Laparoscopy in the diagnosis and treatment of peritoneal metastases. Annals of Laparoscopic and Endoscopic Surgery, 4(42). Retrieved January 16, 2020, from doi: 10.21037/ales.2019.04.04
  5. Schaub, N. P., Alimchandani, M., Quezado, M., Kalina, P., Eberhardt, J. S., Hughes, M. S., … Avital, I. (2013). A novel nomogram for peritoneal mesothelioma predicts survival. Annals of surgical oncology, 20(2), 555–561. Retrieved January 16, 2020, from doi:10.1245/s10434-012-2651-5
  6. Lederman, G. S., Recht, A., Herman, T., Osteen, R., Corson, J., Antman, K. H. (1987). Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer(28). Retrieved January 16, 2020, from doi: 10.1002/1097-0142(19870601)59:11<1882::aid-cncr2820591107>3.0.co;2-0
  7. Kaya, H., Sezgı, C., Tanrıkulu, A. C., Taylan, M., Abakay, O., Sen, H. S., Abakay, A., Kucukoner, M., & Kapan, M. (2014). Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma,61(4), 433-438. Retrieved January 16, 2020, from doi:10.4149/neo_2014_053
  8. Magge, D., Zenati, M.S., Austin, F., Mavanur, A., Sathaiah, M., Ramalingam, L… & Choudry, H.A. (2014). Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis. Annals of Surgical Oncology, 21(4), 1159-1165. Retrieved January 16, 2020, from https://doi.org/10.1245/s10434-013-3358-y
  9. Moffitt Cancer Center. (n.d.). Debulking Cytoreductive Surgery for Ovarian Cancer. Retrieved January 16, 2020, from https://moffitt.org/cancers/ovarian-cancer/debulking-cytoreductive-surgery/
  10. Mesothelioma Applied Research Foundation. (n.d.). Treatment for Peritoneal Mesothelioma. Retrieved January 16, 2020, from https://www.curemeso.org/mesothelioma-treatment-plan/treatment-overview/treatment-for-peritoneal-mesothelioma/
  11. Munkholm-Larsen, S., Cao, C. Q., & Yan, T. D. (2009). Malignant peritoneal mesothelioma. World journal of gastrointestinal surgery, 1(1), 38–48. Retrieved January 16, 2020, from doi:10.4240/wjgs.v1.i1.38
  12. Bagnyukova, T. V., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. (2010). Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?. Cancer biology & therapy, 10(9), 839–853. Retrieved January 16, 2020, from doi:10.4161/cbt.10.9.13738
  13. Marinaccio, A., Corfiati, M., Binazzi, A., Di Marzio, D., Scarselli, A., Ferrante, P., … ReNaM Working Group (2018). The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. Occupational and environmental medicine, 75(4), 254–262. Retrieved January 16, 2020, from doi:10.1136/oemed-2016-104119
  14. Mazurek, J.M., Syamlal, G., Wood, J.M., Hendricks, S.A., & Weston, A. (2017). Malignant Mesothelioma Mortality — United States, 1999–2015. MMWR and Morbidity and Mortality Weekly Report, 66(8), 214-218. Retrieved January 16, 2020, from http://dx.doi.org/10.15585/mmwr.mm6608a3external icon

Call 866-608-8933

Give us a call now to get more information and discuss your options with our team of medical and legal professionals.

Call now to discuss your medical and legal options with a patient advocate.